NVG 222
Alternative Names: NVG-222Latest Information Update: 13 Dec 2023
At a glance
- Originator NovalGen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Dec 2023 NovalGen plans a trial for Cancer in 2024
- 10 Dec 2023 Pharmacokinetics and pharmacodynamics data from preclinical studies in Cancer presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 12 Jan 2023 Preclinical trials in Cancer in United Kingdom (Parenteral) before January 2023 (NovalGen pipeline, January 2023)